TW9 is a potent dual inhibitor simultaneously targeting BET and HDAC proteins with KDs of 0.069 µM, 0.231 µM for BRD4(1), BRD4(2), and an IC50 of 0.29 µM for HDAC1, respectively. TW9 is a newly generated adduct of the BET inhibitor (+)-JQ1 (HY-13030) and class I HDAC inhibitor CI994 (HY-50934). TW9 shows high potency in suppressing tumor growth in pancreatic ductal adenocarcinoma (PDAC). TW9 improves the efficacy of the chemotherapeutic agent Gemcitabine (HY-17026)[1].
Molekulargewicht:
610.13
CAS Nummer:
[2614417-90-0]
Formel:
C32H28ClN7O2S
Target-Kategorie:
Epigenetic Reader Domain,HDAC
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
